Management of NSAID-associated peptic ulcer disease

Luigi Melcarne, Pilar García-Iglesias, Xavier Calvet

Research output: Contribution to journalReview articleResearchpeer-review

44 Citations (Scopus)


© 2016 Informa UK Limited, trading as Taylor & Francis Group. ABSTRACT: Non-steroidal anti-inflammatory drug (NSAID) use increases the risk of gastrointestinal complications such as ulcers or bleeding. The presence of factors like advanced age, history of peptic ulcer, Helicobacter pylori infection and the use of anticoagulants or antiplatelet agents increase this risk further. COX-2 inhibitors and antisecretory drugs, particularly proton pump inhibitors, help to minimize the risk of gastrointestinal complications in high-risk patients. This review presents a practical approach to the prevention and treatment of NSAID-associated peptic ulcer disease and examines the new advances in the rational use of NSAIDs.
Original languageEnglish
Pages (from-to)723-733
JournalExpert Review of Gastroenterology and Hepatology
Issue number6
Publication statusPublished - 2 Jun 2016


  • Cardiovascular risk
  • COX-2 selective inhibitors
  • Gastrointestinal bleeding
  • Gastrointestinal risk
  • Gastroprotection
  • Low dose aspirin
  • Non-steroidal anti-inflammatory drugs
  • NSAID gastropathy
  • Upper gastrointestinal complications


Dive into the research topics of 'Management of NSAID-associated peptic ulcer disease'. Together they form a unique fingerprint.

Cite this